FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to biotechnology and can be used in medical practice. Invention discloses compounds containing CpG oligodeoxynucleotide sequence (SEQ ID NO: 1), at 5'-end linked to the lipid by means of a linker.
EFFECT: invention can be used as an adjuvant in a therapeutic protein composition (SEQ ID NO: 2 and 3) in treating human papillomavirus (HPV)-positive cancer in a patient.
12 cl, 14 dwg, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INTRACELLULAR DELIVERY OF BIOMOLECULES FOR IMMUNE RESPONSE MODULATION | 2019 |
|
RU2819143C2 |
| HPV-SPECIFIC BINDING MOLECULES | 2018 |
|
RU2804664C2 |
| METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH HPV | 2019 |
|
RU2799784C2 |
| ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR THEIR APPLICATION | 2018 |
|
RU2763798C1 |
| VACCINATION USING THE ALPHA 3 DOMAIN OF MICA/B FOR CANCER TREATMENT | 2016 |
|
RU2747296C2 |
| BISPECIFIC MOLECULES, IMMUNOREACTIVE WITH IMMUNE EFFECTOR CELLS EXPRESSING AN ACTIVATING RECEPTOR | 2014 |
|
RU2721707C2 |
| CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND THEIR USE | 2018 |
|
RU2780020C2 |
| BIOLOGICAL MATERIALS FOR MODULATING IMMUNE RESPONSES | 2017 |
|
RU2770060C2 |
| ADVANCED CORONAVIRUS VACCINE | 2022 |
|
RU2816182C2 |
| FUSION CONSTRUCTION CONTAINING CELL PENETRATING PEPTIDE, POLYEPITOPE AND TLR PEPTIDE AGONIST, INTENDED FOR TREATMENT OF CANCER | 2017 |
|
RU2807135C2 |
